Amgen Stock Forecast, Price & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMGN stock has increased by 24.7% and is now trading at $247.72.
View which stocks have been most impacted by COVID-19.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) announced its earnings results on Tuesday, July, 28th. The medical research company reported $4.25 earnings per share for the quarter, beating the Zacks' consensus estimate of $3.81 by $0.44. The medical research company earned $6.21 billion during the quarter, compared to the consensus estimate of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. Amgen's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.97 earnings per share.
View Amgen's earnings history.

Amgen declared a quarterly dividend on Thursday, July 23rd. Stockholders of record on Monday, August 17th will be given a dividend of $1.60 per share on Tuesday, September 8th. This represents a $6.40 annualized dividend and a yield of 2.58%. The ex-dividend date is Friday, August 14th.
View Amgen's dividend history.

Amgen updated its FY20 earnings guidance on Tuesday, July, 28th. The company provided EPS guidance of $15.10-15.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.63. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.38 billion.

27 Wall Street analysts have issued 1-year price objectives for Amgen's stock. Their forecasts range from $185.00 to $300.00. On average, they anticipate Amgen's share price to reach $255.28 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price.
View analysts' price targets for Amgen.

Amgen saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 6,200,000 shares, an increase of 41.2% from the August 15th total of 4,390,000 shares. Based on an average daily volume of 2,630,000 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.1% of the company's shares are sold short.
View Amgen's Short Interest.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and JPMorgan Chase & Co. (JPM).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.34%), BlackRock Inc. (8.32%), FMR LLC (2.92%), Nordea Investment Management AB (1.43%), Bank of New York Mellon Corp (1.14%) and Nuveen Asset Management LLC (0.67%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Advisor Group Holdings Inc., Pzena Investment Management LLC, FMR LLC, Toronto Dominion Bank, LSV Asset Management, Healthcare of Ontario Pension Plan Trust Fund, and AQR Capital Management LLC. Company insiders that have sold Amgen company stock in the last year include David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, BlackRock Inc., Raymond James Financial Services Advisors Inc., Robeco Institutional Asset Management B.V., Marshall Wace North America L.P., Man Group plc, Thrivent Financial for Lutherans, and Sumitomo Mitsui Trust Holdings Inc..
View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $247.72.

Amgen has a market capitalization of $145.09 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]